Momentum is growing behind efforts to ensure new cancer therapies do not enter the market without any strategy for developing the evidence that patients and their doctors need to make informed decisions on whether it [more]
The digital era has opened up huge possibilities for collecting, storing and analysing data. How wonderful if it could be harnessed to answer questions that would allow us to get the best for every patient [more]
My good friend Professor Richard Sullivan wrote an excellent piece for Cancer World on how to reverse the decline in the benefit per cost of cancer interventions. It gave me food for thought. Sullivan gave [more]
‘Value’ is the latest buzzword in cancer: value-based pricing, delivering value for cancer care, enhancing the value offering for cancer technologies… It makes sense, as focusing on the value of interventions we invest in is [more]
When discussing about therapies, particularly in oncology, affordability needs to be addressed as one of the top priorities, along with safety and efficacy of the intervention, and quality and consistency of the evidence: this is [more]
One of the great myths peddled about cancer control is that it is intrinsically affordable. Nothing could be further from the truth. Preventing and treating cancer is the pinnacle of the health system’s mountain. It [more]
In this editorial, Alberto Costa, who has taken over from Kathy Redmond, pays tribute to her achievements, reaffirms the magazines founding principles, and flags up changes to style and content that will expand the reach [more]
Doctors in Tel Aviv teamed up with a photojournalist to learn more about the role of the unsung heroes who place their patientcompanion at the heart of their world. This article was first published in [more]
Our systems for evaluating new therapies are only as good as the accuracy of the judgements we make about how far patients benefit and how far they feel the burden of side-effects and other drawbacks. [more]